| Title |
A Phase 4, open label, safety and efficacy study of Fabrazyme (agalsidase beta) as enzyme replacement therapy in Chinese participants with Fabry disease |
| Description |
Based on the Phase 3 study and its extension study as well as the Phase 4 study results, it was demonstrated that early treatment may alleviate symptoms and prevent further progression of this lethal disease before irreversible damage has occurred.The current study is to evaluate the safety and the efficacy of 1 mg/kg of agalsidase beta every 2 weeks in a Chinese population in the post-marketing setting. |
| Organism |
Homo sapiens |
| Data Type |
Expression Profiling |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA020590 |
| Release Date |
2024-12-31 |
| Submitter |
Nan Chen (cnrj100@126.com) |
| Organization |
Ruijin Hospital, Shanghai jiaotong University School of Medicine |
| Submission Date |
2023-11-07 |